Home / News / Events / Events detail
On June 29th, Dr. Shuai Pan, Director of Process Development of Langhua Pharmaceutical, a subsidiary of Viva Biotech, was invited to give a speech. He focused on sharing fluid chemistry developments following the ICH Q13 guidelines. He also detailed the advantages of continuous manufacturing applications in innovative drug development using the experience and successful cases of Langhua in building fluid chemistry development capabilities.
While speaking on the topic of the role of fluid chemistry in the development of innovative drugs, Dr. Shuai Pan said, "Continuous manufacturing provides more flexibility and options for the design of synthetic routes for drugs and the adoption of a two-way integration of process development, while the device design allows for more diverse methods and means of process development optimization. Continuous technology should be introduced as early as possible to replace multiple segment unit operations with multi-step tandem chemical reactions. This can help achieve sustainability of early API process development and production, effectively avoid many challenges due to scale-up production in later projects, ensure safety, improve efficiency, and reduce pollution from the source of the synthetic process."
Dr. Shuai Pan introduced Langhua's continuous manufacturing process platform, which has a professional team including cutting-edge talents in various fields such as continuous process route design, continuous process development, reactor design, and chemical engineering. Langhua has developed a continuous flow process for various hazardous reactions, such as ozonation, acylation, amination, diazotization, nitration, oxidation, sulfonation, and other hazardous reactions.
Copyright © Viva Biotech All Rights Reserved. 沪ICP备19036061号
- About Us
-
CRO Services
BackCRO ServicesDiscovery Biology Services
- CDMO Services
- EFS Business
- News
- Careers
- Investor Relations
- Contact Us